Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
- 1 February 1993
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 35 (2) , 161-165
- https://doi.org/10.1111/j.1365-2125.1993.tb05681.x
Abstract
1. Cytochrome P450 debrisoquine (CYP2D6) activity is polymorphic and under genetic control. Most Caucasians are extensive metabolizers, but 5%‐10% are poor metabolizers. 2. Restriction fragment length polymorphism analysis of the CYP2D6 locus identifies a 29kb XbaI fragment, either normal (D6‐wt) or mutated, and three mutated XbaI alleles (44kb, 11.5kb and 16 + 9kb). The 44kb allele was initially considered as a poor metabolizer allele owing to a D6‐B mutation, but cases of 44kb allele not carrying the D6‐B, and therefore potentially functional, have been found. The degree of molecular heterogeneity of this allele was investigated by phenotype and genotype analysis of families. 3. Thirty‐one French Caucasian families, representing 117 individuals, possessing at least one 44kb allele in each family were selected. Phenotypes were determined using dextromethorphan, and the XbaI, NcoI and BamH1 RFLPs of 42 independent chromosomes were analyzed. 4. 80% of the XbaI 44kb alleles carried the CYP2D6‐B mutation and had an additional NcoI fragment (12.5kb or 4.8kb). The remaining 20% did not carry the CYP2D6‐B or A mutations and had no extra NcoI fragment. 5. Information on three families demonstrated that 44kb alleles not carrying the CYP2D6‐B mutation were associated with the extensive metabolizer phenotype. 6. We conclude that a substantial percentage of XbaI 44kb alleles is associated with a functional CYP2D gene, and therefore, that the XbaI 44kb allele is not consistently a poor metaboliser allele.Keywords
This publication has 30 references indexed in Scilit:
- Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles ofCYP2D6in a European PopulationDNA and Cell Biology, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- The genetic polymorphism of debrisoquine/sparteine metabolism—molecular mechanismsPharmacology & Therapeutics, 1990
- Detection of debrisoquine hydroxylation phenotypesThe Lancet, 1990
- Molecular genotyping to predict debrisoquine hydroxylation phenotypeThe Lancet, 1990
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990
- Recent Developments in Hepatic Drug OxidationClinical Pharmacokinetics, 1990
- P450 GENES: STRUCTURE, EVOLUTION, AND REGULATIONAnnual Review of Biochemistry, 1987
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977